TSC2 clinical trials at UCSF

1 in progress, 0 open to eligible people

Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Sorry, not currently recruiting here
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
San Francisco, California and other locations

Last updated: March 12, 2024